Inhibikase's CEO said the phase three program has 28 countries approved and 79 sites running. A safety update is planned for 2027, covering 50 patients and 12 weeks of data, with a PVR readout in mid-2028 and pivotal data in mid-2029. The 2027 update is tied to a $55 million financing.
IKT · Inhibikase Therapeutics, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 61%
- Last earnings
- Nov 10, 2026
- Latest filing
- 10-Q · Nov 10
- Price history
- Dec 2020 to Nov 2026
Up next
Latest documents
Inhibikase Therapeutics said the FDA granted orphan drug designation for IKT-001 in July 2026, while Phase 3 IMPROVE-PAH was enrolling across 79 clinical sites; cash, cash equivalents and marketable securities totaled $193.3 million.
Inhibikase Therapeutics reported 28 country regulatory approvals and 79 activated clinical sites for IMPROVE-PAH. Cash, cash equivalents and marketable securities totaled $193.3 million, while quarter-ended net loss was $20.5 million, or $0.10 per share.
Inhibikase Therapeutics said Dennis Berman resigned from its board and committee roles effective October 19, 2026. The board appointed Scott Wasserman as a Class III director the same day, with options to purchase up to 310,000 shares.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents and marketable securities | $193.3M | As of September 30, 2026 | — |
| Clinical sites activated for Phase 3 IMPROVE-PAH study | 79 | As of November 2026 | — |
| Pre-funded warrants outstanding | 60.6M | As of September 30, 2026 | — |
| Shares of common stock outstanding | 140.3M | As of September 30, 2026 | — |
| clinical sites initiated for Phase 3 IMPROVE-PAH study | 43 | Q2 2026 | — |
| country regulatory approvals for Phase 3 IMPROVE-PAH study | 26 | Q2 2026 | — |
| planned Phase 3 IMPROVE-PAH Part A patient enrollment | 140 | Phase 3 IMPROVE-PAH study design | — |
| planned Phase 3 IMPROVE-PAH Part B patient enrollment | 346 | Phase 3 IMPROVE-PAH study design | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IKT
this stock
Inhibikase Therapeutics, Inc.
|
$185.16M | -35.6% | -100.0% | — | 13.9% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 16, 2026
- This year
- 21
Inhibikase's CEO said the phase three program has 28 countries approved and 79 sites running. A safety update is planned for 2027, covering 50 patients and 12 weeks of data, with a PVR readout in mid-2028 and pivotal data in mid-2029. The 2027 update is tied to a $55 million financing.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IKT | -13.2% | -17.0% | -22.4% | -14.8% | -35.6% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -4.6% | -7.8% | -13.2% | -6.1% | -36.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.